Patents by Inventor Sanjita Sasmal
Sanjita Sasmal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240156814Abstract: The present invention provides a method of treating a disease or disorder with at least one SMARCA2/4 degrader, in a subject who are responders to such treatment based on the presence of tumor specific alterations described therein. The present invention also provides the methods for treating prostate cancer in the subjects who are likely to respond to treatment with SMARCA2/4 degraders.Type: ApplicationFiled: January 8, 2024Publication date: May 16, 2024Applicant: Aurigene Oncology LimitedInventors: Muralidhara Ramachandra, Leena Khare Satyam, Sanjita Sasmal, Susanta Samajdar
-
Publication number: 20240051952Abstract: The present invention is related to compounds of structure (I) as hem oxygenase 1 (HOMOX 1) inducers. (Formula I) The present invention is also related a method of con-trolling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.Type: ApplicationFiled: October 6, 2023Publication date: February 15, 2024Inventors: Margaret Biddle, Arthur Kluge, Sanjita Sasmal, Bharat Lagu, Xinyuan Wu, Takashi Ogiyama, Eric Bell
-
Patent number: 11865114Abstract: The present invention provides a method of treating a disease or disorder with at least one SMARCA2/4 degrader, in a subject who are responders to such treatment based on the presence of tumor specific alterations described therein. The present invention also provides the methods for treating prostate cancer in the subjects who are likely to respond to treatment with SMARCA2/4 degraders.Type: GrantFiled: September 11, 2020Date of Patent: January 9, 2024Assignee: Aurigene Oncology LimitedInventors: Muralidhara Ramachandra, Leena Khare Satyam, Sanjita Sasmal, Susanta Samajdar
-
Publication number: 20220177460Abstract: The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. (Formula I) The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.Type: ApplicationFiled: April 8, 2020Publication date: June 9, 2022Inventors: Margaret Biddle, Arthur Kluge, Sanjita Sasmal, Bharat Lagu, Xinyuan Wu, Takashi Ogiyama, Eric Bell
-
Publication number: 20210253564Abstract: The present invention provides pyridazine derivatives of formula (I), which are therapeutically useful as SMARCA2/4 degraders. These compounds are useful in the treatment and/or prevention of diseases or disorders dependent upon SMARCA2/4 in a mammal. The present invention also provides preparation of the compounds and pharmaceutical compositions of at least one of the pyridazine derivatives of formula (I) or a pharmaceutically acceptable salt, or a stereoisomer thereof.Type: ApplicationFiled: April 26, 2019Publication date: August 19, 2021Applicant: Aurigene Discovery Technologies LimitedInventors: Sanjita Sasmal, Susanta Samajdar, Subhendu Mukherjee, Chandrasekhar Abbineni
-
Publication number: 20210077486Abstract: The present invention provides a method of treating a disease or disorder with at least one SMARCA2/4 degrader, in a subject who are responders to such treatment based on the presence of tumor specific alterations described therein. The present invention also provides the methods for treating prostate cancer in the subjects who are likely to respond to treatment with SMARCA2/4 degraders.Type: ApplicationFiled: September 11, 2020Publication date: March 18, 2021Applicant: Aurigene Discovery Technologies LimitedInventors: Muralidhara Ramachandra, Leena Khare Satyam, Sanjita Sasmal, Susanta Samajdar
-
Patent number: 10766888Abstract: The present invention is related to compounds of structure (I) as heme oxygenase 1 (HMOX 1) inducers. The present invention is also related a method of controlling the activity or the amount, or both the activity and the amount, of heme-oxygenase 1 in a mammalian subject. The definitions of the variables are provided herein.Type: GrantFiled: April 8, 2020Date of Patent: September 8, 2020Assignee: Mitobridge Inc.Inventors: Margaret Biddle, Arthur Kluge, Sanjita Sasmal, Bharat Lagu, Xinyuan Wu, Takashi Ogiyama, Eric Bell
-
Patent number: 10590118Abstract: The present disclosure provides bicyclic heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as bromodomain inhibitors; (I), in which R1, R2, R3, R4, L1, L2, Cy1, Cy2, X, n, and dotted line have the same meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders associated as bromodomain inhibitors. The present disclosure also provides preparation of compounds and pharmaceutical formulations comprising at least one of bicyclic heterocyclic derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent, or excipient.Type: GrantFiled: August 1, 2018Date of Patent: March 17, 2020Assignee: ORION CORPORATIONInventors: Susanta Samajdar, Chandrasekhar Abbineni, Sanjita Sasmal, Subramanya Hosahalli
-
Publication number: 20180339982Abstract: The present disclosure provides bicyclic heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as bromodomain inhibitors; (I), in which R1, R2, R3, R4, L1, L2, Cy1, Cy2, X, n, and dotted line have the same meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders associated as bromodomain inhibitors. The present disclosure also provides preparation of compounds and pharmaceutical formulations comprising at least one of bicyclic heterocyclic derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent, or excipient.Type: ApplicationFiled: August 1, 2018Publication date: November 29, 2018Inventors: Susanta SAMAJDAR, Chandrasekhar Abbineni, Sanjita Sasmal, Subramanya Hosahalli
-
Patent number: 10077259Abstract: The present disclosure provides bicyclic heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as bromodomain inhibitors; (I), in which R1, R2, R3, R4, L1, L2, Cy1, Cy2, X, n, and dotted line have the same meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders associated as bromodomain inhibitors. The present disclosure also provides preparation of compounds and pharmaceutical formulations comprising at least one of bicyclic heterocyclic derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent, or excipient.Type: GrantFiled: January 6, 2015Date of Patent: September 18, 2018Assignee: Orion CorporationInventors: Susanta Samajdar, Chandrasekhar Abbineni, Sanjita Sasmal, Subramanya Hosahalli
-
Publication number: 20160368906Abstract: The present disclosure provides bicyclic heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as bromodomain inhibitors; (I), in which R1, R2, R3, R4, L1, L2, Cy1, Cy2, X, n, and dotted line have the same meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders associated as bromodomain inhibitors. The present disclosure also provides preparation of compounds and pharmaceutical formulations comprising at least one of bicyclic heterocyclic derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent, or excipient.Type: ApplicationFiled: January 6, 2015Publication date: December 22, 2016Applicant: Orion CorporationInventors: Susanta SAMAJDAR, Chandrasekhar ABBINENI, Sanjita SASMAL, Subramanya HOSAHALLI
-
Publication number: 20150299120Abstract: The present invention relates to a compound of formula (I-1) in free form or in pharmaceutically acceptable salt form in which the substituents are as defined in the specification; to its preparation, to its use as a medicament and to medicaments comprising it. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: March 1, 2013Publication date: October 22, 2015Inventors: Mark Gary BOCK, Chetan PANDIT, Sanjita SASMAL, Thomas ULLRICH
-
Patent number: 9051326Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: July 25, 2012Date of Patent: June 9, 2015Assignee: NOVARTIS AGInventors: Mark Gary Bock, Bharat Lagu, Chetan Pandit, Sanjita Sasmal, Thomas Ullrich
-
Publication number: 20140329876Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I), in which the substituents are as defined in the specification; to compounds of formula (I) for use as androgen receptor modulators. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: July 25, 2012Publication date: November 6, 2014Applicant: NOVARTIS AGInventors: Mark Gary Bock, Bharat Lagu, Chetan Pandit, Sanjita Sasmal, Thomas Ullrich